Yield10 Bioscience (NASDAQ:YTEN) Downgraded by Zacks Investment Research

Zacks Investment Research lowered shares of Yield10 Bioscience (NASDAQ:YTEN) from a hold rating to a sell rating in a research report report published on Saturday, Zacks.com reports.

According to Zacks, “Yield10 Bioscience, Inc. is an agricultural bioscience company. It focuses on the development of disruptive technologies for improvement in crop yield to enhance global food security. The company is working on new approaches, to improve fundamental elements of plant photosynthetic efficiency and optimizing carbon metabolism for better production. It operates primarily in Saskatoon, Saskatchewan, Canada. Yield10 Bioscience, Inc., formerly known as Metabolix, Inc., is based in Woburn, Massachusetts. “

YTEN has been the subject of a number of other research reports. Maxim Group reiterated a buy rating and set a $3.00 price target on shares of Yield10 Bioscience in a research note on Friday, May 31st. Aegis reiterated a buy rating and set a $2.00 price target on shares of Yield10 Bioscience in a research note on Tuesday, August 13th. Finally, National Securities reiterated a buy rating and set a $5.00 price target on shares of Yield10 Bioscience in a research note on Tuesday, August 13th.

Shares of YTEN opened at $0.96 on Friday. The company has a debt-to-equity ratio of 1.17, a current ratio of 3.33 and a quick ratio of 4.49. The stock has a 50-day moving average of $0.92 and a 200-day moving average of $1.03. The company has a market cap of $11.96 million, a PE ratio of -1.04 and a beta of 3.21. Yield10 Bioscience has a one year low of $0.68 and a one year high of $1.77.

Yield10 Bioscience (NASDAQ:YTEN) last issued its earnings results on Monday, August 12th. The specialty chemicals company reported ($0.15) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.21) by $0.06. The company had revenue of $0.32 million during the quarter. Yield10 Bioscience had a negative return on equity of 145.61% and a negative net margin of 1,320.21%. Analysts expect that Yield10 Bioscience will post -0.66 EPS for the current fiscal year.

An institutional investor recently raised its position in Yield10 Bioscience stock. Renaissance Technologies LLC raised its stake in shares of Yield10 Bioscience Inc (NASDAQ:YTEN) by 9.5% in the second quarter, according to its most recent 13F filing with the SEC. The fund owned 478,176 shares of the specialty chemicals company’s stock after purchasing an additional 41,500 shares during the period. Renaissance Technologies LLC owned approximately 3.83% of Yield10 Bioscience worth $463,000 as of its most recent SEC filing. 7.80% of the stock is owned by hedge funds and other institutional investors.

Yield10 Bioscience Company Profile

Yield10 Bioscience, Inc, an agricultural bioscience company, engages in developing disruptive technologies for enhancing crop yield in the United States and Canada. The company, through its Smart Carbon Grid for Crops and T3 platforms, is involved in improving fundamental crop yield through enhanced photosynthetic carbon capture, as well as increased carbon utilization efficiency to increase seed yield.

Read More: What is the Rule of 72?

Get a free copy of the Zacks research report on Yield10 Bioscience (YTEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Yield10 Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Yield10 Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.